BMS 933043

Drug Profile

BMS 933043

Alternative Names: BMS-933043

Latest Information Update: 29 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 10 Jul 2014 Discontinued - Phase-I for Schizophrenia (In volunteers) in USA (PO)
  • 31 Dec 2013 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in USA (NCT01605994)
  • 01 Dec 2013 Bristol-Myers Squibb completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01605994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top